Corgi Robots and Humanoids ETF (CBOT)

On our desk, evaluating CBOT's liquidity is a primary concern. With total assets sitting around $1.87 million and an average daily volume scraping roughly 30 shares in certain intervals, entering or exiting sizable blocks without moving the spread is practically impossible. We are advising execution clients to use strict limit orders if they touch this ticker at all.

Watching the macro sentiment unfold across retail forums and institutional filings, CBOT is caught in a classic micro-cap thematic trap. Corgi Strategies has built a genuinely compelling portfolio covering humanoid systems and AI software stacks, but the market is heavily discounting products that fail to clear baseline asset thresholds under $10 million.

As a quant reviewing the risk profile, Morningstar's assignment of an extreme risk score of 102 aligns with our internal metrics. The fund's beta sits at 1.40 to 1.60, meaning it aggressively amplifies broader tech corrections, yet its persistent negative alpha confirms that investors are taking on outsized volatility without getting compensated in return.

In our technical review of the Cboe BZX listing, the 0.35% expense ratio is relatively standard for an actively managed niche product. However, when paired with a net asset value around $27.08 and an intraday price oscillating near $25.23, the wide bid-ask friction completely erodes any structural cost advantage offered by the management fee.

Looking at the Q2 2026 institutional reports, we see exactly one hedge fund maintaining a stake valued at roughly $2.2 million. While the underlying thematic focus on surgical robots, actuators, and warehouse automation is structurally sound for the next decade, institutional capital is simply sitting on the sidelines until assets under management scale up significantly.